Abstract
The outcomes of patients with newly diagnosed multiple myeloma (NDMM) have substantially improved over the last decade. Besides improved staging, diagnostic and prognostic tools leading to better risk-stratified approaches, a major contributing factor has been better induction regimens. The major emphasis of the current clinical research is on the development of induction regimens capable of producing a deep and durable remission as measured by minimal residual disease negativity, which correlates with a better overall survival. This review explores the current changing landscape of induction therapy in NDMM and discusses implications for the current clinical practice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
